News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516, OTC: EPGNY) announces today that the Company successfully issued convertible bonds with a nominal amount of EUR 500,000 to YA Global Master SVP Ltd. (“Yorkville”) excluding pre-emptive rights to existing shareholders. The bonds were issued at 95% of their nominal amount, carry no interest, have a term until August 5, 2014 and are convertible into up to 112,678 shares of Epigenomics. The conversion price equals the volume weighted average share price during a five day period prior to the time of conversion less a 5% discount.
Further details regarding terms and conditions in connection with the issuance of convertible bonds according to the agreement with Yorkville were announced by the ad hoc notification dated August 18, 2013.

– End of Ad hoc –

Contact Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386

Epigenomics’ legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.